Key statistics
52-week range
| Open | 1.50 |
|---|---|
| High | 1.55 |
| Low | 1.50 |
| Bid | 1.51 |
| Offer | 1.55 |
| Previous close | 1.45 |
| Average volume | 60.41k |
|---|---|
| Shares outstanding | 1.54m |
| Free float | 936.70k |
| P/E (TTM) | -- |
| Market cap | 8.92m USD |
| EPS (TTM) | -5.87 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 20:57 GMT.
More ▼
- Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
- Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
- Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
- Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
- Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
- Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
- Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25
- Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
- Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis
- Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
More ▼
